What is the Lincoln Pharmaceuticals Ltd share price today?

The share price of NSE:LINCOLN-EQ on 01 Oct 2026 (as of 15:04:07 IST) is ₹582.1.

What is the NSE:LINCOLN-EQ 52 week high low price?

Over the past 52 weeks (as of 01 Oct 2026), the NSE:LINCOLN-EQ 52 week high low range shows a high of ₹770 and a low of ₹440.

What is the Lincoln Pharmaceuticals Ltd market cap?

As on 01 Oct 2026, Lincoln Pharmaceuticals Ltd market cap is ₹11722400000.

What is the shareholding pattern of Lincoln Pharmaceuticals Ltd Stock?

The shareholding pattern of Lincoln Pharmaceuticals Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 49.78% Foreign Institutional Investors (FII): 4.6% Domestic Institutional Investors (DII): 0.27% Mutual Funds: 0% Retail & Others: 45.35% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Lincoln Pharmaceuticals Ltd?

The Price-to-Earnings (PE) ratio of Lincoln Pharmaceuticals Ltd is 12.1535, and the Price-to-Book (PB) ratio is 1.492, as on 01 Oct 2026.

Lincoln Pharmaceuticals Share Price

542.75-5.95 (-1.08%)

+3.52% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

-1.08%

1 Week

-2.79%

1 Month

-12.95%

3 Month

-9.80%

6 Month

-7.58%

YTD

+12.15%

1 Year

+3.52%

5 Year

+42.32%

10 Year

+137.79%

Max

+152.44%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

542.55

538.05

440.00

High

560.00

572.75

630.90

648.40

770.00

About

Lincoln Pharmaceuticals Ltd is engaged in the manufacture and marketing of affordable therapeutic products. The product range of the company includes Tablets ,Capsules,Injectables,Syrups and Ointments.

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

ZYDUSLIFENSE

LAURUSLABSNSE

CIPLANSE

DRREDDYNSE

MANKINDNSE

AUROPHARMANSE

LUPINNSE

LINCOLNNSE

LTP

1W Low

1W High

Market cap (₹)

1730.2-29.8 (-1.69%)

1725.50

1776.60

4,24,466Cr

9050.5-289.5 (-3.10%)

9027

9431.50

2,46,222Cr

4579-77.9 (-1.67%)

4551.80

4682

1,76,301Cr

1133.6+16.1 (1.44%)

1107.30

1139.80

1,12,818Cr

2033.1-3.5 (-0.17%)

2007.80

2069.20

1,10,823Cr

1307.3+6.3 (0.48%)

1300.20

1333.30

1,07,447Cr

1215.2+18.2 (1.52%)

1196.90

1250.70

1,03,471Cr

2322.8-45.7 (-1.93%)

2317.50

2426.80

97,850Cr

1668.6-24.4 (-1.44%)

1660.10

1715

96,836Cr

1947.3-9.2 (-0.47%)

1925.70

1964.90

89,629Cr

541.6-16.7 (-2.99%)

538.05

572.75

1,102Cr

Lincoln Pharmaceuticals Share Price

542.75-5.95 (-1.08%)

+3.52% past 1 Year

Financial overview

Compounded Sales Growth

10 years5%

5 years10%

3 years10%

Last year8%

Compounded Profit Growth

10 years14%

5 years7%

3 years6%

Last year7%

Stock Price CAGR

10 years9%

5 years8%

3 years3%

1 year5%

Return on Equity

10 years16%

5 years15%

3 years14%

Last year12%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
5%	10%	10%	8%
14%	7%	6%	7%
9%	8%	3%	5%
16%	15%	14%	12%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

ZYDUSLIFE

LAURUSLABS

CIPLA

DRREDDY

MANKIND

AUROPHARMA

LUPIN

LINCOLN

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,751	₹424466 Cr	35.09	12.07	62.82	₹11479 Cr
9,127	₹246222 Cr	84.18	34.04	128.41	₹2568 Cr
4,576.1	₹176301 Cr	80.83	16.72	97.06	₹2163 Cr
1,115.4	₹112818 Cr	25	9.42	62.53	₹5040 Cr
2,036.6	₹110823 Cr	101.36	6.8	29.25	₹889 Cr
1,315.5	₹107447 Cr	31.88	9.77	57.87	₹3879 Cr
1,223	₹103471 Cr	32.11	5.32	63.99	₹4196 Cr
2,340.6	₹97850 Cr	47.9	13.75	71.08	₹1913 Cr
1,667.8	₹96836 Cr	26.08	17.95	96.84	₹3505 Cr
1,931.8	₹89629 Cr	16.21	30.95	154.35	₹5333 Cr
542.75	₹1102 Cr	11.43	18.09	55.6	₹88 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Name

Net Revenue

Other Income

Total Revenue

Total Expenditure

Operating Profit

Interest Expense

PBT

Net Profit

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021	Sep 2021	Jun 2021	Mar 2021	Dec 2020	Sep 2020	Jun 2020	Mar 2020	Dec 2019	Sep 2019	Jun 2019	Mar 2019	Dec 2018	Sep 2018	Jun 2018	Mar 2018	Dec 2017	Sep 2017	Jun 2017	Mar 2017	Dec 2016	Sep 2016	Jun 2016	Mar 2016	Dec 2015	Sep 2015	Jun 2015	Mar 2015	Dec 2014	Sep 2014	Jun 2014	Mar 2014	Dec 2013	Sep 2013	Jun 2013	Mar 2013	Dec 2012	Sep 2012
₹177 Cr	₹187 Cr	₹166 Cr	₹163 Cr	₹154 Cr	₹168 Cr	₹147 Cr	₹161 Cr	₹147 Cr	₹142 Cr	₹146 Cr	₹156 Cr	₹136 Cr	₹112 Cr	₹134 Cr	₹141 Cr	₹123 Cr	₹103 Cr	₹120 Cr	₹127 Cr	₹122 Cr	₹80 Cr	₹115 Cr	₹126 Cr	₹104 Cr	₹78 Cr	₹99 Cr	₹113 Cr	₹97 Cr	₹79 Cr	₹84 Cr	₹103 Cr	₹100 Cr	₹67 Cr	₹80 Cr	₹90 Cr	₹150 Cr	₹121 Cr	₹72 Cr	₹75 Cr	₹89 Cr	₹120 Cr	₹108 Cr	₹95 Cr	₹76 Cr	₹79 Cr	₹68 Cr	₹78 Cr	₹49 Cr	₹67 Cr	₹53 Cr	₹56 Cr	₹40 Cr	₹60 Cr	₹52 Cr	₹55 Cr
₹24 Cr	-₹4 Cr	₹15 Cr	₹7 Cr	₹15 Cr	-₹7 Cr	₹9 Cr	₹10 Cr	₹10 Cr	₹7 Cr	₹11 Cr	₹9 Cr	₹8 Cr	₹4 Cr	₹6 Cr	₹6 Cr	₹6 Cr	₹2 Cr	₹3 Cr	₹3 Cr	₹2 Cr	₹3 Cr	₹73 L	₹60 L	₹2 Cr	₹4 Cr	₹3 Cr	₹3 Cr	₹1 Cr	-₹87 L	₹38 L	₹4 Cr	₹2 Cr	₹86 L	₹3 Cr	₹3 Cr	₹3 Cr	₹21 L	₹3 Cr	₹3 Cr	₹4 Cr	₹9 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹202 Cr	₹183 Cr	₹181 Cr	₹171 Cr	₹169 Cr	₹161 Cr	₹156 Cr	₹171 Cr	₹158 Cr	₹150 Cr	₹157 Cr	₹165 Cr	₹143 Cr	₹116 Cr	₹140 Cr	₹146 Cr	₹130 Cr	₹104 Cr	₹123 Cr	₹131 Cr	₹124 Cr	₹82 Cr	₹115 Cr	₹127 Cr	₹106 Cr	₹83 Cr	₹102 Cr	₹115 Cr	₹98 Cr	₹78 Cr	₹85 Cr	₹107 Cr	₹102 Cr	₹68 Cr	₹83 Cr	₹93 Cr	₹153 Cr	₹121 Cr	₹75 Cr	₹78 Cr	₹93 Cr	₹129 Cr	₹108 Cr	₹95 Cr	₹76 Cr	₹79 Cr	₹68 Cr	₹78 Cr	₹49 Cr	₹67 Cr	₹53 Cr	₹56 Cr	₹40 Cr	₹60 Cr	₹52 Cr	₹55 Cr
₹154 Cr	₹166 Cr	₹146 Cr	₹142 Cr	₹134 Cr	₹145 Cr	₹126 Cr	₹136 Cr	₹128 Cr	₹127 Cr	₹120 Cr	₹127 Cr	₹117 Cr	₹98 Cr	₹109 Cr	₹114 Cr	₹109 Cr	₹87 Cr	₹99 Cr	₹100 Cr	₹99 Cr	₹66 Cr	₹97 Cr	₹98 Cr	₹84 Cr	₹72 Cr	₹87 Cr	₹90 Cr	₹80 Cr	₹70 Cr	₹73 Cr	₹85 Cr	₹78 Cr	₹59 Cr	₹65 Cr	₹76 Cr	₹145 Cr	₹118 Cr	₹65 Cr	₹65 Cr	₹75 Cr	₹118 Cr	₹96 Cr	₹85 Cr	₹65 Cr	₹72 Cr	₹62 Cr	₹67 Cr	₹43 Cr	₹62 Cr	₹47 Cr	₹51 Cr	₹36 Cr	₹53 Cr	₹49 Cr	₹50 Cr
₹52 Cr	₹21 Cr	₹39 Cr	₹33 Cr	₹39 Cr	₹20 Cr	₹33 Cr	₹38 Cr	₹33 Cr	₹25 Cr	₹41 Cr	₹40 Cr	₹28 Cr	₹21 Cr	₹33 Cr	₹35 Cr	₹23 Cr	₹19 Cr	₹26 Cr	₹33 Cr	₹27 Cr	₹18 Cr	₹21 Cr	₹30 Cr	₹24 Cr	₹13 Cr	₹16 Cr	₹27 Cr	₹20 Cr	₹10 Cr	₹14 Cr	₹24 Cr	₹26 Cr	₹11 Cr	₹19 Cr	₹18 Cr	₹10 Cr	₹4 Cr	₹12 Cr	₹15 Cr	₹19 Cr	₹12 Cr	₹13 Cr	₹12 Cr	₹11 Cr	₹7 Cr	₹6 Cr	₹12 Cr	₹7 Cr	₹5 Cr	₹7 Cr	₹5 Cr	₹5 Cr	₹8 Cr	₹3 Cr	₹6 Cr
₹26 L	₹27 L	₹30 L	₹23 L	₹21 L	₹37 L	₹73 L	₹35 L	₹44 L	₹50 L	₹16 L	₹39 L	₹42 L	₹1 Cr	₹33 L	₹14 L	₹41 L	₹57 L	₹31 L	₹20 L	₹38 L	₹58 L	₹39 L	-₹8 L	₹67 L	-₹56 L	₹1 Cr	₹58 L	₹65 L	₹79 L	₹71 L	₹2 Cr	₹1 Cr	₹94 L	₹1 Cr	₹1 Cr	₹2 Cr	₹1 Cr	₹1 Cr	₹2 Cr	₹2 Cr	₹4 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹2 Cr	₹48 L	₹1 Cr	₹2 Cr	₹1 Cr	₹1 Cr
₹48 Cr	₹17 Cr	₹35 Cr	₹29 Cr	₹35 Cr	₹16 Cr	₹29 Cr	₹35 Cr	₹29 Cr	₹22 Cr	₹38 Cr	₹37 Cr	₹25 Cr	₹17 Cr	₹31 Cr	₹32 Cr	₹21 Cr	₹17 Cr	₹24 Cr	₹31 Cr	₹25 Cr	₹15 Cr	₹18 Cr	₹29 Cr	₹21 Cr	₹12 Cr	₹13 Cr	₹25 Cr	₹18 Cr	₹8 Cr	₹11 Cr	₹20 Cr	₹23 Cr	₹8 Cr	₹16 Cr	₹15 Cr	₹7 Cr	₹1 Cr	₹9 Cr	₹12 Cr	₹15 Cr	₹6 Cr	₹10 Cr	₹9 Cr	₹8 Cr	₹3 Cr	₹4 Cr	₹9 Cr	₹4 Cr	₹1 Cr	₹4 Cr	₹4 Cr	₹3 Cr	₹5 Cr	₹1 Cr	₹4 Cr
₹36 Cr	₹12 Cr	₹29 Cr	₹20 Cr	₹28 Cr	₹12 Cr	₹21 Cr	₹26 Cr	₹24 Cr	₹19 Cr	₹28 Cr	₹28 Cr	₹19 Cr	₹13 Cr	₹22 Cr	₹24 Cr	₹15 Cr	₹11 Cr	₹18 Cr	₹23 Cr	₹18 Cr	₹13 Cr	₹13 Cr	₹21 Cr	₹15 Cr	₹9 Cr	₹11 Cr	₹19 Cr	₹13 Cr	₹9 Cr	₹9 Cr	₹15 Cr	₹16 Cr	₹7 Cr	₹12 Cr	₹11 Cr	₹5 Cr	₹1 Cr	₹7 Cr	₹9 Cr	₹11 Cr	₹4 Cr	₹6 Cr	₹7 Cr	₹7 Cr	₹2 Cr	₹3 Cr	₹7 Cr	₹3 Cr	₹77 L	₹3 Cr	₹3 Cr	₹3 Cr	₹5 Cr	₹1 Cr	₹3 Cr

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Minority Interest

Secured Loans

Unsecured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Miscellaneous Expenses not written off

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010	Mar 2009
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹20 Cr	₹20 Cr	₹20 Cr	₹20 Cr	₹20 Cr	₹20 Cr	₹20 Cr	₹20 Cr	₹20 Cr	₹20 Cr	₹16 Cr	₹16 Cr	₹16 Cr	₹16 Cr	₹16 Cr	₹16 Cr	₹11 Cr	₹8 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹8 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹1 Cr
₹738 Cr	₹652 Cr	₹573 Cr	₹482 Cr	₹413 Cr	₹346 Cr	₹293 Cr	₹249 Cr	₹204 Cr	₹172 Cr	₹117 Cr	₹95 Cr	₹83 Cr	₹73 Cr	₹64 Cr	₹61 Cr	₹42 Cr	₹28 Cr
₹738 Cr	₹652 Cr	₹573 Cr	₹482 Cr	₹413 Cr	₹346 Cr	₹293 Cr	₹249 Cr	₹204 Cr	₹172 Cr	₹117 Cr	₹95 Cr	₹83 Cr	₹73 Cr	₹64 Cr	₹61 Cr	₹42 Cr	₹28 Cr
₹758 Cr	₹672 Cr	₹593 Cr	₹502 Cr	₹433 Cr	₹366 Cr	₹313 Cr	₹269 Cr	₹224 Cr	₹192 Cr	₹141 Cr	₹111 Cr	₹99 Cr	₹89 Cr	₹81 Cr	₹77 Cr	₹53 Cr	₹36 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹38 L	₹36 L	₹33 L	₹30 L	₹19 L	₹3 Cr	₹4 Cr	₹4 Cr	₹4 Cr	₹0	₹0	₹0
₹0	₹0	₹0	₹0	₹0	₹14 L	₹85 L	₹2 Cr	₹7 Cr	₹12 Cr	₹24 Cr	₹15 Cr	₹16 Cr	₹14 Cr	₹12 Cr	₹3 Cr	₹26 Cr	₹12 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹10 Cr	₹3 Cr	₹3 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹4 Cr
₹14 Cr	₹13 Cr	₹11 Cr	₹8 Cr	₹6 Cr	₹6 Cr	₹5 Cr	₹6 Cr	₹7 Cr	₹6 Cr	₹7 Cr	₹5 Cr	₹4 Cr	₹5 Cr	₹5 Cr	₹4 Cr	₹3 Cr	₹2 Cr
₹6 Cr	₹5 Cr	₹4 Cr	₹5 Cr	₹5 Cr	₹4 Cr	₹4 Cr	₹4 Cr	₹4 Cr	₹3 Cr	₹3 Cr	₹3 Cr	₹3 Cr	₹3 Cr	₹3 Cr	₹3 Cr	₹0	₹0
₹2 Cr	₹73 L	₹10 L	₹25 Cr	₹0	₹16 Cr	₹33 Cr	₹17 Cr	₹7 Cr	₹10 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹22 Cr	₹19 Cr	₹15 Cr	₹38 Cr	₹11 Cr	₹26 Cr	₹43 Cr	₹28 Cr	₹25 Cr	₹32 Cr	₹34 Cr	₹33 Cr	₹26 Cr	₹25 Cr	₹22 Cr	₹11 Cr	₹30 Cr	₹18 Cr
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹85 Cr	₹85 Cr	₹72 Cr	₹51 Cr	₹72 Cr	₹57 Cr	₹51 Cr	₹44 Cr	₹43 Cr	₹32 Cr	₹30 Cr	₹45 Cr	₹67 Cr	₹48 Cr	₹42 Cr	₹23 Cr	₹18 Cr	₹11 Cr
₹14 Cr	₹15 Cr	₹15 Cr	₹15 Cr	₹10 Cr	₹13 Cr	₹9 Cr	₹11 Cr	₹11 Cr	₹13 Cr	₹15 Cr	₹12 Cr	₹14 Cr	₹16 Cr	₹16 Cr	₹12 Cr	₹4 Cr	₹63 L
₹4 Cr	₹0	₹1 Cr	₹2 Cr	₹2 Cr	₹0	₹4 Cr	₹30 Cr	₹49 Cr	₹45 Cr	₹53 Cr	₹51 Cr	₹48 Cr	₹55 Cr	₹47 Cr	₹40 Cr	₹0	₹0
₹33 Cr	₹31 Cr	₹29 Cr	₹29 Cr	₹27 Cr	₹24 Cr	₹16 Cr	₹15 Cr	₹10 Cr	₹9 Cr	₹2 Cr	₹7 Cr	₹2 Cr	₹27 L	₹0	₹2 Cr	₹6 Cr	₹7 Cr
₹137 Cr	₹131 Cr	₹117 Cr	₹96 Cr	₹111 Cr	₹95 Cr	₹80 Cr	₹100 Cr	₹113 Cr	₹99 Cr	₹100 Cr	₹114 Cr	₹131 Cr	₹118 Cr	₹105 Cr	₹77 Cr	₹28 Cr	₹19 Cr
₹916 Cr	₹822 Cr	₹725 Cr	₹637 Cr	₹555 Cr	₹487 Cr	₹437 Cr	₹399 Cr	₹363 Cr	₹324 Cr	₹275 Cr	₹262 Cr	₹260 Cr	₹237 Cr	₹212 Cr	₹165 Cr	₹111 Cr	₹73 Cr
₹4 Cr	₹3 Cr	₹23 L	₹23 L	₹23 L	₹1 Cr	₹2 Cr	₹2 Cr	₹23 Cr	₹20 Cr	₹15 Cr	₹13 L	₹13 L	₹0	₹0	₹5 Cr	₹4 Cr	₹5 Cr
₹4 Cr	₹0	₹1 Cr	₹2 Cr	₹2 Cr	₹52 L	₹5 Cr	₹34 Cr	₹61 Cr	₹64 Cr	₹78 Cr	₹76 Cr	₹68 Cr	₹76 Cr	₹69 Cr	₹46 Cr	₹27 Cr	₹16 Cr
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹274 Cr	₹252 Cr	₹237 Cr	₹197 Cr	₹171 Cr	₹142 Cr	₹147 Cr	₹138 Cr	₹128 Cr	₹108 Cr	₹121 Cr	₹88 Cr	₹82 Cr	₹79 Cr	₹49 Cr	₹37 Cr	₹28 Cr	₹22 Cr
₹83 Cr	₹70 Cr	₹57 Cr	₹47 Cr	₹39 Cr	₹31 Cr	₹24 Cr	₹17 Cr	₹11 Cr	₹5 Cr	₹22 Cr	₹22 Cr	₹17 Cr	₹14 Cr	₹11 Cr	₹9 Cr	₹7 Cr	₹6 Cr
₹191 Cr	₹182 Cr	₹179 Cr	₹151 Cr	₹132 Cr	₹111 Cr	₹123 Cr	₹121 Cr	₹117 Cr	₹103 Cr	₹98 Cr	₹66 Cr	₹65 Cr	₹65 Cr	₹38 Cr	₹28 Cr	₹21 Cr	₹17 Cr
₹5 Cr	₹4 Cr	₹3 Cr	₹7 Cr	₹16 Cr	₹2 Cr	₹4 L	₹2 Cr	₹29 L	₹7 Cr	₹3 Cr	₹3 Cr	₹2 Cr	₹2 Cr	₹14 Cr	₹4 Cr	₹1 Cr	₹0
₹26,000	₹26,000	₹26,000	₹26,000	₹26,000	₹40,000	₹9 L	₹9 L	₹9 L	₹9 L	₹55,400	₹55,400	₹41 L	₹41 L	₹41 L	₹34,200	₹34,200	₹19,200
₹26,000	₹26,000	₹26,000	₹26,000	₹26,000	₹40,000	₹9 L	₹9 L	₹9 L	₹9 L	₹55,400	₹55,400	₹41 L	₹41 L	₹41 L	₹34,200	₹34,200	₹19,200
₹111 Cr	₹111 Cr	₹80 Cr	₹88 Cr	₹32 Cr	₹47 Cr	₹51 Cr	₹36 Cr	₹19 Cr	₹24 Cr	₹27 Cr	₹12 Cr	₹43 Cr	₹46 Cr	₹39 Cr	₹13 Cr	₹0	₹0
₹12 L	₹0	₹9,000	₹6,000	₹2 Cr	₹45 L	₹3 L	₹33 L	₹34 L	₹36 L	₹0	₹0	₹0	₹0	₹0	₹60,899	₹0	₹0
₹307 Cr	₹297 Cr	₹263 Cr	₹245 Cr	₹182 Cr	₹160 Cr	₹174 Cr	₹159 Cr	₹136 Cr	₹134 Cr	₹128 Cr	₹81 Cr	₹111 Cr	₹114 Cr	₹91 Cr	₹45 Cr	₹22 Cr	₹17 Cr
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹209 Cr	₹174 Cr	₹139 Cr	₹91 Cr	₹97 Cr	₹81 Cr	₹34 Cr	₹18 Cr	₹11 Cr	₹10 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹80 Cr	₹79 Cr	₹77 Cr	₹70 Cr	₹73 Cr	₹47 Cr	₹47 Cr	₹36 Cr	₹45 Cr	₹37 Cr	₹27 Cr	₹22 Cr	₹24 Cr	₹19 Cr	₹21 Cr	₹26 Cr	₹23 Cr	₹14 Cr
₹161 Cr	₹166 Cr	₹162 Cr	₹136 Cr	₹116 Cr	₹113 Cr	₹101 Cr	₹122 Cr	₹109 Cr	₹91 Cr	₹81 Cr	₹119 Cr	₹89 Cr	₹75 Cr	₹65 Cr	₹40 Cr	₹31 Cr	₹23 Cr
₹33 Cr	₹22 Cr	₹14 Cr	₹34 Cr	₹19 Cr	₹14 Cr	₹15 Cr	₹8 Cr	₹15 Cr	₹12 Cr	₹13 Cr	₹12 Cr	₹10 Cr	₹15 Cr	₹17 Cr	₹13 Cr	₹13 Cr	₹5 Cr
₹2 Cr	₹3 Cr	₹2 Cr	₹2 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹66 L	₹5 L	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹124 Cr	₹81 Cr	₹70 Cr	₹57 Cr	₹68 Cr	₹72 Cr	₹64 Cr	₹54 Cr	₹45 Cr	₹39 Cr	₹26 Cr	₹29 Cr	₹26 Cr	₹14 Cr	₹18 Cr	₹41 Cr	₹21 Cr	₹14 Cr
₹609 Cr	₹525 Cr	₹463 Cr	₹391 Cr	₹373 Cr	₹328 Cr	₹263 Cr	₹239 Cr	₹227 Cr	₹190 Cr	₹147 Cr	₹181 Cr	₹149 Cr	₹123 Cr	₹122 Cr	₹120 Cr	₹89 Cr	₹56 Cr
₹472 Cr	₹394 Cr	₹346 Cr	₹295 Cr	₹262 Cr	₹233 Cr	₹182 Cr	₹139 Cr	₹113 Cr	₹90 Cr	₹47 Cr	₹67 Cr	₹18 Cr	₹5 Cr	₹17 Cr	₹43 Cr	₹61 Cr	₹37 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹81,199	₹1 L
₹916 Cr	₹822 Cr	₹725 Cr	₹637 Cr	₹555 Cr	₹487 Cr	₹437 Cr	₹399 Cr	₹363 Cr	₹324 Cr	₹275 Cr	₹262 Cr	₹260 Cr	₹237 Cr	₹212 Cr	₹165 Cr	₹111 Cr	₹73 Cr
₹378	₹335	₹296	₹251	₹216	₹183	₹157	₹135	₹112	₹96	₹82	₹68	₹61	₹55	₹50	₹47	₹47	₹47
₹378	₹335	₹296	₹251	₹216	₹183	₹157	₹135	₹112	₹96	₹82	₹68	₹61	₹55	₹50	₹47	₹47	₹47

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010	Mar 2009
₹116 Cr	₹109 Cr	₹122 Cr	₹100 Cr	₹96 Cr	₹84 Cr	₹67 Cr	₹62 Cr	₹46 Cr	₹37 Cr	₹33 Cr	₹20 Cr	₹12 Cr	₹10 Cr	₹5 Cr	₹8 Cr	₹9 Cr	₹7 Cr
₹6 Cr	₹96 L	-₹17 Cr	-₹23 L	₹1 Cr	₹5 Cr	₹9 Cr	₹9 Cr	₹12 Cr	₹11 Cr	₹14 Cr	₹11 Cr	₹13 Cr	₹9 Cr	₹14 Cr	₹7 Cr	₹1 Cr	₹2 Cr
₹10 Cr	₹9 Cr	-₹16 Cr	-₹31 Cr	₹2 Cr	₹20 L	₹14 Cr	-₹1 Cr	-₹22 Cr	-₹13 Cr	₹5 Cr	-₹3 Cr	-₹18 Cr	-₹32 Cr	-₹6 Cr	-₹48 Cr	-₹18 Cr	-₹5 Cr
₹131 Cr	₹119 Cr	₹89 Cr	₹69 Cr	₹100 Cr	₹89 Cr	₹90 Cr	₹70 Cr	₹36 Cr	₹35 Cr	₹52 Cr	₹28 Cr	₹7 Cr	-₹14 Cr	₹13 Cr	-₹33 Cr	-₹8 Cr	₹4 Cr
₹106 Cr	₹93 Cr	₹63 Cr	₹39 Cr	₹76 Cr	₹69 Cr	₹75 Cr	₹53 Cr	₹27 Cr	₹25 Cr	₹45 Cr	₹25 Cr	₹5 Cr	-₹16 Cr	₹12 Cr	-₹34 Cr	-₹11 Cr	₹2 Cr
-₹98 Cr	-₹79 Cr	-₹57 Cr	-₹37 Cr	-₹78 Cr	-₹64 Cr	-₹31 Cr	-₹18 Cr	-₹12 Cr	-₹25 Cr	-₹42 Cr	₹7 Cr	₹1 Cr	-₹16 Cr	-₹27 Cr	-₹11 Cr	-₹6 Cr	-₹4 Cr
₹16 L	-₹6 Cr	-₹5 Cr	-₹5 Cr	-₹3 Cr	-₹6 Cr	-₹38 Cr	-₹36 Cr	-₹11 Cr	₹30 L	-₹3 Cr	-₹32 Cr	-₹11 Cr	₹29 Cr	₹16 Cr	₹45 Cr	₹25 Cr	₹3 Cr
₹8 Cr	₹8 Cr	₹70 L	-₹2 Cr	-₹5 Cr	-₹70 L	₹7 Cr	-₹1 Cr	₹3 Cr	-₹14 L	-₹41 L	-₹96 L	-₹4 Cr	-₹3 Cr	₹82 L	-₹9 L	₹9 Cr	₹1 Cr
₹13 Cr	₹6 Cr	₹5 Cr	₹7 Cr	₹11 Cr	₹12 Cr	₹5 Cr	₹7 Cr	₹3 Cr	₹3 Cr	₹4 Cr	₹5 Cr	₹9 Cr	₹12 Cr	₹12 Cr	₹12 Cr	₹5 Cr	₹3 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹9 L	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹22 Cr	₹13 Cr	₹6 Cr	₹5 Cr	₹7 Cr	₹11 Cr	₹12 Cr	₹5 Cr	₹7 Cr	₹3 Cr	₹3 Cr	₹4 Cr	₹5 Cr	₹9 Cr	₹12 Cr	₹12 Cr	₹13 Cr	₹5 Cr

Fundamental Ratios

Consolidated

Standalone

No results found

Lincoln Pharmaceuticals Share Price

542.75-5.95 (-1.08%)

+3.52% past 1 Year

02 Jan 25+9D

Bid/Ask

Price

Greeks

Stradle

Custom

CALLS

Qty/ots

PUTS

Open a free Demat account in minutes to start investing and screening .

Lincoln Pharmaceuticals Share Price

542.75-5.95 (-1.08%)

+3.52% past 1 Year

Shareholding summary

Promoters

49.78%

FII

4.6%

DII

0.27%

Others

45.35%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
49.78%	49.78%	49.78%	49.78%	49.78%	49.78%
4.60%	5.20%	4.70%	4.73%	5.13%	5.00%
0.27%	1.08%	0.01%	0.01%	0.01%	0.00%
0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
45.35%	43.94%	45.51%	45.48%	45.08%	45.22%

Bulk & block deals

Name

Nk Securities Research Private Limited

Qe Securities Llp

Nk Securities Research Private Limited

Qe Securities Llp

Greenx Wealth Multihorizons Opportunity Fund

Nk Securities Research Private Limited

Musigma Securities

Irage Broking Services Llp

Nk Securities Research Private Limited

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
29 Apr 2026	Purchase	14.75 Cr	₹707.51	2.08 L	Bulk	1.040784	NSE
29 Apr 2026	Purchase	7.71 Cr	₹701.46	1.10 L	Bulk	0.548865	NSE
29 Apr 2026	Sell	14.76 Cr	₹707.93	2.08 L	Bulk	1.040784	NSE
29 Apr 2026	Sell	7.59 Cr	₹709.28	1.07 L	Bulk	0.534152	NSE
12 Feb 2026	Purchase	9.97 Cr	₹603.07	1.65 L	Bulk	0.82505	NSE
07 Aug 2025	Purchase	16.52 Cr	₹599.49	2.76 L	Bulk	1.375882	NSE
07 Aug 2025	Purchase	9.70 Cr	₹604.97	1.60 L	Bulk	0.800312	NSE
07 Aug 2025	Purchase	8.28 Cr	₹600.74	1.38 L	Bulk	0.688213	NSE
07 Aug 2025	Purchase	5.54 Cr	₹599.35	92.37 K	Bulk	0.461175	BSE
07 Aug 2025	Sell	16.55 Cr	₹600.39	2.76 L	Bulk	1.375882	NSE

Insider trading & SAST

Client name

Munjal Mahendrabhai Patel & Pacs

Munjal Mahendrabhai Patel

Munjal Mahendrabhai Patel & Pacs

Munjal Mahendrabhai Patel

Patel Nishitkumar Maheshbhai

Renukaben Maheshbhai Patel

Patel Nishitkumar Mahesbhai

Renukaben Maheshbhai Patel

Patel Nishitkumar Maheshbhai

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
25 Jun 2024	Promoter	Acquisition	0.07	13.37	0	—	13.50 K	04 Jun 2024	Market	26,78,800	SAST	29(2)	—
06 Jun 2024	Promoter & Director	Acquisition	0.0674	13.37	73.10 L	₹541.50	13.50 K	04 Jun 2024	Market Purchase	26,78,800	Insider Trading	—	Equity Shares
04 Jun 2024	Promoter	Acquisition	0.17	13.3	0	—	35 K	31 May 2024 - 03 Jun 2024	Market	26,65,300	SAST	29(2)	—
03 Jun 2024	Promoter & Director	Acquisition	0.074889	13.21	84.69 L	₹564.60	15 K	31 May 2024	Market Purchase	26,45,300	Insider Trading	—	Equity Shares
03 Jun 2024	Promoter & Director	Acquisition	0.099852	13.3	1.14 Cr	₹568.25	20 K	03 Jun 2024	Market Purchase	26,65,300	Insider Trading	—	Equity Shares
05 Mar 2024	Promoter	Disposal	0.01	0.77	0	—	1 K	26 Feb 2024	Market	1,54,400	SAST	29(2)	—
05 Mar 2024	Promoter	Disposal	0.01	0.49	0	—	1.50 K	26 Feb 2024	Market	98,047	SAST	29(2)	—
05 Mar 2024	Promoter	Disposal	0.01	0.76	0	—	1 K	27 Feb 2024	Market	1,53,400	SAST	29(2)	—
04 Mar 2024	Promoter	Disposal	0.31	0.5	0	—	62.50 K	23 Feb 2024	Market	99,547	SAST	29(2)	—
04 Mar 2024	Promoter	Disposal	0.13	0.78	0	—	26.50 K	23 Feb 2024	Market	1,55,400	SAST	29(2)	—

Lincoln Pharmaceuticals Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Lincoln Pharmaceuticals Share Price

Lincoln Pharmaceuticals Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Lincoln Pharmaceuticals Share Price

Lincoln Pharmaceuticals Share Price

Oscillators

Moving averages

Lincoln Pharmaceuticals Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Lincoln Pharmaceuticals Share Price

Corporate Actions

Company details

Lincoln Pharmaceuticals Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Lincoln Pharmaceuticals Share Price

News

Lincoln Pharma targets Rs 1,000 crore revenue in three years

Lincoln Pharma reports flat EBITDA margin with higher quarterly EBITDA

Lincoln Pharma reports higher Q1 revenue at Rs 177 crores

Lincoln Pharma reports higher Q1 net profit on yearly basis

Lincoln Pharma Q4 EBITDA declines year-on-year with margin compression reported

Lincoln Pharma posts flat Q4 profit with healthy double-digit revenue growth

Lincoln Pharma reports Profit after tax of 11.63 Crores, in the March 2026 quarter

Lincoln Pharma - Quaterly Results

Lincoln Pharma reports Profit after tax of 28.60 Crores, in the December 2025 quarter

Lincoln Pharmaceuticals Q3 EBITDA Slightly Down YoY at Rs 23.60 Crores, Margin Contracts to 14.2%

Lincoln Pharmaceuticals Q3 FY26 Revenue Growth YoY at 12.6%

Lincoln Pharmaceuticals Q3FY26 Net Profit Rises 37.5% YoY to Rs 28.60 Crores.

Lincoln Pharma reports Profit after tax of 19.98 Crores, in the September 2025 quarter

Lincoln Pharmaceuticals Q2 FY25 net profit declines to Rs 20 crore versus Rs 26.3 crore YoY.

Lincoln Pharmaceuticals Q2 FY26 reports lower EBITDA and margin compared to previous year.

Lincoln Pharmaceuticals informs about press release

Lincoln Pharmaceuticals informs about AGM

Lincoln Pharma - Quaterly Results

Lincoln Pharma - Quaterly Results

Lincoln Pharma - Quaterly Results

Lincoln Pharmaceuticals Ltd Share Price Today

Lincoln Pharmaceuticals Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator